ChondroFiller injection prices in the UK

Three fixed price points cover the vast majority of ChondroFiller injection cases in the UK:

• £3,000 — one box, suited to a single focal cartilage defect
• £5,500 — two boxes
• £8,000 — three boxes

These figures apply to standard joint treatments including the knee. For larger joints such as the hip or shoulder, where greater product volume is typically required, the all-inclusive price generally falls in the £6,500–£9,500 range.

Every tier is fully inclusive. A single quoted figure covers the initial consultation, MRI review, real-time ultrasound guidance during the procedure, the collagen scaffold implant itself, intravenous antibiotic cover on the day, and a six-week follow-up appointment. Because the injection is carried out as an outpatient procedure under local anaesthetic — taking approximately 30–45 minutes — there are no separate theatre fees, no anaesthetist's charges, and no hospital admission costs to add on afterwards.

The exact tier is confirmed only once MRI imaging has been reviewed and the defect size established; any figure provided before that point should be treated as a guide rather than a final cost.

Why ChondroFiller costs more than a standard joint injection

The cost gap between ChondroFiller and a standard joint injection begins with how the product is regulated. ChondroFiller is a CE-marked Class III medical device — the highest risk tier in European medical device regulation — because it actively participates in tissue biology rather than providing temporary symptom relief alone.

In plain terms, the collagen scaffold hardens inside the defect and acts as a physical framework for the body's own repair cells. Technically, this is in-situ gelation: the acellular murine-derived Type I collagen material transitions from fluid to a structured matrix, creating the conditions for matrix-induced chondrogenesis — a process in which the patient's own progenitor cells migrate into the scaffold and begin laying down new tissue. Hyaluronic acid works as a lubricant; corticosteroids reduce inflammation; neither carries regenerative intent.

That regulatory classification — and the manufacturing and import overhead it demands — is the primary reason the product, supplied by Meidrix Biomedicals GmbH in Germany under prescription, costs substantially more than a standard injection. Class III devices face intensive pre-market scrutiny, controlled supply chains, and ongoing clinical surveillance, all of which are built into the product price.

Because the injection is delivered as an outpatient procedure, the total cost nonetheless sits well below the surgical cartilage repair options discussed in the following section.

How it compares to surgical cartilage repair costs

Placing ChondroFiller's price bands alongside the main surgical alternatives makes the decision context clearer.

Microfracture — £4,000–£7,000. The cheapest surgical route, yet also the most limited in durability. Microfracture produces fibrocartilage rather than hyaline-like tissue, and published series report reoperation rates of up to 41%. There is a further consideration: the drilling damages the subchondral bone plate in a way that can complicate any future repair attempt. Its use has been declining as these limitations have become better established.

OATS (osteochondral autograft) — approximately £14,000. A single-stage procedure that transplants a plug of bone and cartilage from a lower-load area of the same joint. It suits lesions in the 1–2 cm² range and provides structurally sound tissue, but donor-site morbidity — discomfort or weakness at the harvest point — is a meaningful consideration for active patients.

ACI / MACI — £15,000–£35,000+. Two separate operations are required: a biopsy to harvest the patient's own chondrocytes, a laboratory culturing phase costing £10,000–£17,000 alone, and then a second surgical implantation. Total private costs in the UK consistently sit in the £25,000–£35,000 band and are often higher. Outside a handful of NHS-commissioned specialist centres, ACI and MACI are largely unavailable privately.

STACi / osteochondral allograft replacement — approximately £28,000. Reserved for larger or post-traumatic defects where autograft tissue is insufficient. All surgical options listed here involve general or spinal anaesthesia, theatre booking, and anaesthetist fees.

Against this backdrop, ChondroFiller's published evidence base reports an IKDC improvement of approximately 30 points and a reoperation rate of 3–8% — outcomes comparable to ACI/MACI. No direct randomised trials comparing ChondroFiller against surgical repair currently exist; these figures come from the ChondroFiller evidence base, not head-to-head comparative studies. That caveat noted, the procedural contrast is straightforward: ACI/MACI requires two theatre episodes and a cell-culturing period measured in weeks; a ChondroFiller injection is an outpatient procedure completed under local anaesthetic, with no theatre episode at any stage.

NHS funding, insurance, and self-pay

ChondroFiller injection is not NHS-funded, and it is not covered as standard by Bupa or AXA. For the vast majority of patients, this is a self-pay treatment — that is the baseline expectation to plan around.

Insurance approvals are not impossible, but they are the exception rather than the rule and require proactive groundwork. Case-by-case approvals have been reported with Bupa, Aviva, and WPA when the procedure is billed under CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500. Patients with private health insurance who wish to explore this route should contact their insurer directly, cite these codes, and request a written pre-authorisation decision before any appointment is booked. Verbal agreement does not constitute cover, and retrospective claims are unlikely to succeed. Insurance policies and approval criteria change; any decision received should be confirmed in writing and treated as specific to that claim.

For patients who are self-funding, the all-inclusive pricing structure described earlier means there are no additional fees to budget for after the quoted figure — no separate consultation invoice, no follow-up charge, and no theatre or anaesthetist cost, since the procedure does not involve any of those elements.

What shapes your individual cost

The single factor that determines which price tier applies is the number and size of cartilage defects — and that cannot be confirmed without imaging.

MRI scanning is the diagnostic tool that maps defect size and distribution across the joint. ChondroFiller injection is indicated for focal cartilage defects of up to approximately 3 cm² per box; where two or three defects are present, or where a single lesion extends beyond that threshold, additional boxes are required, with total coverage extending to around 6 cm². That box count is what moves a patient between the £3,000, £5,500, and £8,000 tiers.

Joint type is the second variable. The hip and shoulder require greater product volume than the knee, which is why pricing for those joints runs in a separate range, as set out in the opening section.

Grading also shapes suitability. ChondroFiller injection is best suited to ICRS or Outerbridge grade III–IV focal defects in an otherwise reasonably preserved joint. Patients with diffuse or advanced osteoarthritis across multiple compartments are likely to need a different clinical conversation — not because options run out, but because joint preservation or replacement discussion becomes the more appropriate pathway at that stage.

For all these reasons, the initial consultation — which includes MRI review — is where both suitability and a confirmed cost figure can be properly established.

Getting an assessment at London Cartilage Clinic

For most patients, the practical upshot of this article is straightforward: ChondroFiller injection is a self-funded outpatient treatment priced between £3,000 and £8,000 depending on defect count and joint, with no surgical or theatre costs on top. The step that converts that estimate into a confirmed figure is an initial consultation paired with MRI review — imaging is the only reliable way to confirm defect size, ICRS grade, and how many boxes are required.

At London Cartilage Clinic on Harley Street, Professor Paul Y. F. Lee and the clinical team review imaging to determine whether the ChondroFiller injection pathway is appropriate or whether a different cartilage restoration option better fits the clinical picture. Patients based outside London may be directed to MSK Doctors group sites in Lincolnshire and Grantham for treatment delivery. To arrange an assessment, visit londoncartilage.com.